Pan-European Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: October 11, 2007
Last updated: November 19, 2007
Last verified: November 2007
The survey try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.·


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Pan-European Survey on the Under Treatment of Hypercholesterolemia

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The number and percentage of patients achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.

Enrollment: 6500
Study Start Date: January 2006
Study Completion Date: November 2007

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00542867

Sponsors and Collaborators
Principal Investigator: M. Hermans UCL
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00542867     History of Changes
Other Study ID Numbers: SRP-CB-CRE-2006/01
Study First Received: October 11, 2007
Last Updated: November 19, 2007
Health Authority: Belgium: Federal Agency for Medicinal Products and Health

Keywords provided by AstraZeneca:
Third Joint European Task Force guidelines

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on November 25, 2015